

FORM PTO 1449 (modified)  
U.S. DEPARTMENT OF COMMERCEATTY DOCKET NO.  
085933/0122

SERIAL NO.

Unassigned

09/972,190

APPLICANT  
Anuschirwan PEYMAN et al.FILING DATE  
October 9, 2001

GROUP

Unassigned

1624

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
RR	A1	5,707,994	01/1998	Ikeda et al.	514	255	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
RR	A2	0 820 991	01/1998	Europe	—	—	
RR	A3	94/12181	06/1994	WIPO	—	—	
RR	A4	94/08577	04/1994	WIPO	—	—	
RR	A5	0 528 586	02/1993	Europe	—	—	
RR	A6	0 528 587	02/1993	Europe	—	—	
RR	A7	95/32710	12/1995	WIPO	—	—	
RR	A8	96/00574	01/1996	WIPO	—	—	
RR	A9	96/00730	01/1996	WIPO	—	—	
RR	A10	98/00395	01/1998	WIPO	—	—	Abstract

## OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

RR	A11	JARDINE, Paul Da Silva et al., "Anti-Osteoporosis Agents", <u>Annual Reports in Medicinal Chemistry</u> (31) Chapter 22, pp. 211-220, (1996).
RR	A12	HORTON, M.A. et al., "Arg-Gly-Asp (RGD) Peptides and the Anti-Vitronectin Receptor Antibody 23C6 Inhibit Dentine Resorption and Cell Spreading by Osteoclasts", <u>Experimental Cell Research</u> , pp. 368-375, (1991).
RR	A13	SATO M. et al., "Echistatin is a Potent Inhibitor of Bone Resorption in Culture", <u>The Journal of Cell Biology</u> , 111, pp. 1713-1723, (October 1990).
RR	A14	FISHER, John E et al., "Inhibition of Osteoclastic Bone Resorption in Vivo by Echistatin, an Arginyl-Glycyl-Aspartyl" (RGD)-Containing Protein", <u>Endocrinology</u> , (132)3, pp. 1411-1413, (1993).
RR	A15	BROWN, Steven L. et al., "Stimulation of migration of human aortic smooth muscle cells by vitronectin implications for atherosclerosis", <u>Cardiovascular Research</u> (28), pp. 1815-1820, (1994).
RR	A16	BROOKS, Peter C. et al., "Integrin $\alpha_v\beta_3$ Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels, <u>Cell</u> (79), pp. 1157-1164, (December 1994).

EXAMINER

RR Pappas

DATE CONSIDERED

4-17-03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO 1449 (modified)  
U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO.  
085933/0122

SERIAL NO.

Unassigned 09 K172,190

APPLICANT  
Anuschirwan PEYMAN et al.

FILING DATE  
October 9, 2001

GROUP

Unassigned 1624



# U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

# FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
RR	A17	97/21726	06/97	WIPO		

# OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

RR	A18	ENGLEMAN, V. Wayne et al., "Cell Adhesion Integrin as Pharmaceutical Targets", <u>Annual Reports in Medicinal Chemistry</u> , (31) Chapter 20, pp. 191-200, (1996).				
RR	A19	STRACKE, Mary L. et al., "Tumor Cell Motility and Invasion", <u>Encyclopedia of Cancer</u> (Vol. III), pp. 1855-1867, (1997).				
RR	A20	HILLIS, Graham S., et al., "Integrins and disease", <u>Clinical Science</u> (91), pp. 639-650, (1996).				
RR	A21	CARRON, Christopher P. et al., "A Peptidomimetic Antagonist of the Integrin $\alpha_v\beta_3$ Inhibits Leydig Cell Tumor Growth and the Development of Hypercalcemia of Malignancy", <u>Cancer Research</u> (58), pp. 1930-1935, (5/98).				
RR	A22	FRIEDLANDER, Martin et al., "Definition of Two Angiogenic Pathways by Distinct $\alpha_v$ Integrins", <u>Science</u> , (270) pp. 1500-1502, (December 1995).				
RR	A23	FLEISHER, David et al., "Improved oral drug delivery: solubility limitations overcome by the use of prodrugs" <u>Advanced Drug Delivery Reviews</u> (19), pp. 115-130, (1996), Elsevier, Paris.				
RR	A24	BUNDGAARD, Hans, "Novel chemical approaches in prodrug design, <u>Drugs of the Future</u> (16)5, pp. 443-458, (1991).				
RR	A25	SAULNIER, Mark G. et al., "An Efficient Method for the Synthesis of Guanidino Prodrugs", <u>Bioorganic &amp; Medical Chemistry Letters</u> (4)16, pp. 1985-1990, (1994).				
RR	A26	SAFADI, Muhammad et al., "Phosphoryloxymethyl Carbamates and Carbonates—Novel Water Soluble Prodrugs for Amines and Hindered Alcohols", <u>Pharmaceutical Research</u> (10)9, pp. 1350-1355, (1993).				
RR	A27	KÖNIG, W. et al., "Perchloric acid in peptide chemistry," <u>Peptides</u> pp. 143-145, (1990)				

EXAMINER

RR Kaur

DATE CONSIDERED

4-17-03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO 1449 (modified)  
U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO.  
085933/0122

SERIAL NO.

Unassigned 09/972,190

APPLICANT  
Anuschirwan PEYMAN et al.

FILING DATE  
October 9, 2001

GROUP

Unassigned 1624

0857 U.S. PTO  
09/972190



# U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
RR	A28	6,017,925	01/00	Duggan	514	300	

# FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
RR	A29	98/31359	07/98	WIPO	—	—		
RR	A30	0 933 367	08/99	Europe	—	—		

# OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

RR	A31		STAAB, H.A., "Synthesis Using Heterocyclic Amids (Azolides)", <u>Angew. Chem. Internat. Edit.</u> (1)7, pp. 351-367, (1962).
RR	A32		YATOHGO, Takemi et al., "Novel Purification of Vitronectin from Human Plasma by Heparin Affinity Chromatography, <u>Cell Structure and Function</u> 13, pp. 281-292, (1988).
RR	A33		STORGARD, Chris M. et al., "" (103)1, Decreased angiogenesis and arthritic disease in rabbits treated with An $\alpha_3\beta_3$ antagonist," <u>The Journal of Clinical Investigation</u> (103)1, pp. 47-54, (January 1999).
RR	A34		YUE, Tian-Li et al., "SK&F107260, a Cyclic RGD Peptide, Inhibits Integrin $\alpha_v\beta_3$ -Mediated Vascular Smooth Muscle Cell Migration, <i>in vitro</i> , and Reduces Neointima Formation Following Balloon Injury to the Rat Carotid Artery, <i>in vivo</i> , ", <u>Pharmacology Review and Communications</u> , (100)9, pp. 9-18, (1998).
RR	A35		YAMAMOTO, Michiko et al., "The Integrin Ligand Echistatin Prevents Bone Loss in Ovariectomized Mice and Rats", <u>Endocrinology</u> , (139)3, pp. 1411-1419, (1998).

EXAMINER

RR R. R. Campbell

DATE CONSIDERED

4-17-03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.